newsfilter
← Earnings
Earnings Releases·

Indivior — Third Quarter 2026 Earnings Summary

  • **Record Financial Performance:** Q3 2026 net revenue rose 13% YoY to $356 million, driven by a 22% YoY increase in SUBLOCADE revenue to a record $267 million; GAAP net income surged to $137 million ($1.12 EPS) and Adjusted EBITDA jumped 76% YoY to $211 million.
  • **Full-Year Outlook Confirmed:** The company remains on track to meet previously communicated 2026 standalone guidance, projecting net revenue of $1.295–$1.365 billion and Adjusted EBITDA of $700–$740 million, with guidance ceasing upon the merger completion.
  • **Strategic Merger and Capital Return:** Indivior shareholders approved an all-stock merger with Supernus scheduled to close on November 2, 2026, forming a combined CNS-focused entity trading as Supernus Inc. (SUPN), alongside a special cash dividend declared contingent on the transaction closing.
  • **Balance Sheet and Cost Structure:** While cash and investments stood at $332 million, the current portion of long-term debt increased significantly to $488 million as of September 30, 2026, reflecting debt restructuring associated with the merger and dividend.
Company
INDIVIOR PHARMACEUTICALS INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic